Substantial progress has been made in the targeted therapy of breast cancer, with three new targeted therapies licensed for advanced breast cancer over the last two years. Targeted therapies block the growth and spread of cancer by interfering in specific biological processes responsible for cancer cell growth. Therefore targeted therapies may be more effective and less harmful to normal cells than other cancer treatments, such as traditional chemotherapy that targets all rapidly dividing cells. The most well known targeted therapy at the moment is trastuzumab (Herceptin).
A new thematic series in Breast Cancer Research brings together the translational research behind these new approaches, as well as reviewing treatments with early evidence of efficacy that are still …
Post by Rabia Begum
Obesity is emerging as a major risk factor to cancer susceptibility. With obesity rates on the rise around the world, this has major health and policy implications for us all.
This link between cancer and obesity was debated at the Metabolism, Diet and Disease Conference in 2012, in which the focus was on metabolic factors in common between obesity and cancer and potential strategies for intervening to reduce the associated health risks.
The panel, including Michael Pollak and Stephen Hursting, also discussed the fact that anti-cancer agents are less effective in obese cancer patients, and that the metabolic link to different cancers may not always be the same. Take a look at some of the highlights from …
The incidence of gallbladder cancer varies significantly worldwide, with very high rates in South America, Japan, China and Eastern Europe and lower rates in the US and UK. Interestingly gallbladder cancer is also twice as common in women than men, which arguably may be due to increased exposure to the hormone oestrogen.
The prognosis for living with gallbladder cancer is very poor, and thus research into finding an effective treatment is crucially important. Xiao Liang and colleagues have recently published a promising early study on this subject in Cell & Bioscience, reporting the results of a preliminary experiment using the antimalarial drug chloroquine to aid treatment of the cancer.
Gallbladder cancer is notoriously difficult to treat as …
The epidemiological evidence now seems overwhelming: obesity is a major cause of cancer, which will rise with the rising tide of obesity in the well fed Western world. Elio Riboli will speak on what epidemiology can tell us about how our physiology and habits contribute to the probability of developing cancer at the second BMC conference on Metabolism, diet and disease, and in an interview for BMC Biology he explained how perceptions have changed in the past ten years.
Red and processed meat have notoriously been incriminated in increased risk of cancer, an association recently confirmed by a paper in our sister journal BMC Medicine, with fruit and vegetables, long advocated for health and long …
When we published Luc Tappy’s Q&A on fructose toxicity two years ago at the time of our first conference on Metabolism diet and disease, he took the line that fructose is harmless to people not at special risk of developing metabolic disease, but could reasonably and on the whole should be avoided by people who are at risk, since it is dispensible and may, for reasons connected with our metabolism and homeostatic circuitry, exacerbate any tendency to overeating and obesity.
He didn’t say it was addictive and best avoided altogether, along with any other sweeteners – which is the conclusion that Lew Cantley now arrives at, in a short interview for BMC Biology to introduce some …
Genome Biology would like to announce that we are now inviting Research, Method or Software manuscript submissions for publication in a special issue on cancer progression and heterogeneity, which is planned for late summer 2014.
Recent advances, such as single-cell sequencing technologies, are allowing us to study cancer genomics at a depth that was not previously possible. Now, Genome Biology wants to highlight the importance of this field by publishing a special issue with an emphasis on cancer progression and heterogeneity. We will consider Research, Method and Software manuscripts describing insights into, or developing methods for studying, all aspects of the genomics of cancer progression, including the clonal evolution of cancer, cancer heterogeneity, metastasis, single-cell …
In Spring/Summer 2014, Genome Medicine will publish a special issue focusing on Cancer Epigenomics, guest edited by Stephan Beck (University College London).
Large-scale sequencing and high-throughput ‘omic studies of a wide variety of cancers have revealed epigenomic variations, including DNA methylation, histone modification and mutations in genes involved in epigenetic regulation. These have provided mechanistic insights into cancer initiation and progression, and are revealing novel approaches and targets for therapeutic intervention.
This special issue aims to bring together translational findings in cancer epigenomics that have the potential to inform new approaches for screening, diagnosis, prevention and treatment of cancer.
The editors are accepting submissions of Research, Method, Database, Software and Open Debate manuscripts. The deadline for submissions …
With great fanfare comes great cynicism, and so it should: science is built on a tug-of-war between novel claims and kneejerk skeptism, and the probity that follows. When a sound bite leaked out of last year's ENCODE publications, of which Genome Biology was a participatory journal, that '80% of the human genome has a function', evolutionary biologists were cynical all right, and they took to the journals to say so.
While some of the disagreement hinged on the semantics of the word 'function', a key sticking point was the scientific validity of declaring a stretch of the genome functional when there is no evidence for evolutionary constraint on its constituent DNA sequence. In other words, how …
Launching today with BioMed Central is Basic and Clinical Andrology, a continuation of the French journal Andrologie, which was previously published as a subscription journal by Springer in French. The journal will now be open access and published in English. In keeping with its French past the journal will also publish the abstracts of articles in the French language, just as many other BioMed Central journals that support multilingual abstracts.
Andrology is the field of medicine that covers male health, specifically for problems relating to the male reproductive system. Basic and Clinical Andrology will cover all aspects of male reproductive and sexual health in both human and animal …
Guest blog post by Professor Mike McConnell, Stanford University School of Medicine, USA.
Chemotherapy can injure heart muscle, leading to heart failure, but this damage may not be apparent until many years later. Children receiving chemotherapy are of particular concern, as the risk of heart failure increases as they age into adulthood. A safe, noninvasive method to detect this damage could identify high risk patients and prompt earlier preventive therapy.
In an article published today in Journal of Cardiovascular Magnetic Resonance, researchers from the University of Alberta, Canada present their result from a study looking at MRI of the heart in 30 children two years after chemotherapy. They found changes in the heart muscle even though overall …